Navigation Links
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
Date:1/14/2009

market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors, the success of the joint venture in commercializing and developing Zevalin, the ability of the joint venture to accelerate top-line revenues in the near-term, the ability to integrate Zevalin into Spectrum's commercial, marketing and medical affairs teams, the results of complete safety and progression free survival information for pixantrone which is still being assembled, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the determination by the FDA that the PIX301 trial is insufficient to support an NDA filing, marketing approval review of the OPAXIO MAA may not result in a marketing approval in Europe, the costs of developing, producing and selling Zevalin, OPAXIO, pixantrone and brostallicin, the risk that Novartis may not elect to participate in the development and marketing of OPAXIO or may not exercise its option with regard to pixantrone, the Company may be unable to complete its recapitalization plan as it continues to have a substantial amount of debt outstanding, the quarterly interest expense associated with the debt is significant and the Company's operating expenses continue to exceed its net revenues, the Company will be successful in reducing its operating expenses, and the Company will continue to need to raise capital to fund its operations. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Media Contact:
     Dan Eramian
     T: 206.2
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 Today the ... round of grants for the Brain Research through ... aims to develop and revolutionize new methods of ... the human brain. This first round of grants ... 2014 was allocated to more than 100 investigators ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
... England, July 20, 2011 , ... of its randomised, placebo-controlled, double blind Phase II,Study, ... Progressive Multiple Sclerosis (SPMS). Standard clinical,measures and assessment ... as novel biomarkers will be used to investigate ...
... 2011 ReSearch Pharmaceutical Services, Inc. (RPS), a ... II-IV clinical development solutions to the biopharmaceutical and ... additions to its Operational and Senior Management team. ... as Chief Information Officer and Executive Vice President, ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: ... second quarter financial results for the period ended June 30, 2011, ... will host a conference call and webcast that day at 4:30 ... Conference Call Details To access the live ...
Cached Biology Technology:Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3PDL BioPharma Announces Second Quarter 2011 Financial Results on July 27, 2011 2
(Date:9/30/2014)... Ill. --- Do we think of nature as something that ... we need to "preserve?" Or do we think of ourselves ... part of nature, but what about a house? , ... are also reflected in our actions, our speech and in ... with the University of Washington, the American Indian Center of ...
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
Breaking Biology News(10 mins):The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... 2008) -- Cell Press has been chosen by ... journal from January 2009. The Biophysical Society ... Journal content and that of the Cell Press ... and Structure. , For more than 50 years ...
... . , Iron is vital to human life; ... that makes our blood red and supplies our cells with ... thought that iron deposits in the brain contribute to certain ... Alzhiemers. A malfunction of the blood transporter transferrin may be ...
... new modeling approach to estimate sea ice thickness. This ... The model was developed by scientists with ... Sciences, Moscow. Using this new technique, the ... to 2003. Results showed that average ice thickness and ...
Cached Biology News:Cell Press announces new partnership with the Biophysical Society 2Rusty worms in the brain 2New method to estimate sea ice thickness 2
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: